- Home
- STNG vs KNSA Comparison
STNG vs KNSA Comparison
Compare STNG & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STNG | KNSA |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | Monaco | United Kingdom |
| Employees | 24 | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.5B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | STNG | KNSA |
|---|---|---|
| Price | $81.38 | $54.35 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | ★ $83.33 | $60.86 |
| AVG Volume (30 Days) | ★ 950.8K | 795.8K |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.22% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | N/A | ★ 0.27 |
| Revenue | N/A | ★ $677,564,000.00 |
| Revenue This Year | $4.31 | $37.48 |
| Revenue Next Year | N/A | $17.87 |
| P/E Ratio | ★ $10.06 | $198.13 |
| Revenue Growth | N/A | ★ 60.09 |
| 52 Week Low | $37.96 | $25.71 |
| 52 Week High | $82.75 | $54.31 |
Technical Indicators
Market Signals| Indicator | STNG | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 65.32 | 71.23 |
| Support Level | $72.41 | $40.67 |
| Resistance Level | $81.85 | N/A |
| Average True Range (ATR) | 3.00 | 2.24 |
| MACD | 0.51 | 1.15 |
| Stochastic Oscillator | 88.80 | 100.00 |
Price Performance
Historical ComparisonAbout STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.